Clinical Trial Update: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing HX008 plus chemotherapy to pembrolizumab plus chemotherapy as first-line treatment for advanced or metastatic nonsquamous non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HX008
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Taizhou Hanzhong biomedical co. LTD | Conditions: Nonsquamous Non-small Cell Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN